These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30903275)

  • 1. Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
    Kessler T; Koschmieder S; Schliemann C; Crysandt M; Mikesch JH; von Stillfried S; Stelljes M; Pohlen M; Lenz G; Kirsch A; Vehring K; Wardelmann E; Hartmann W; Bormann E; Gerss J; Brümmendorf TH; Müller-Tidow C; Berdel WE
    Ann Hematol; 2019 Jun; 98(6):1393-1401. PubMed ID: 30903275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
    Grande E; Capdevila J; Castellano D; Teulé A; Durán I; Fuster J; Sevilla I; Escudero P; Sastre J; García-Donas J; Casanovas O; Earl J; Ortega L; Apellaniz-Ruiz M; Rodriguez-Antona C; Alonso-Gordoa T; Díez JJ; Carrato A; García-Carbonero R
    Ann Oncol; 2015 Sep; 26(9):1987-1993. PubMed ID: 26063633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
    Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Sideras K; Morris JC; McIver B; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Goh BC; Tang H; Ivy SP; Erlichman C; ; ;
    Lancet Oncol; 2010 Oct; 11(10):962-72. PubMed ID: 20851682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Koinis F; Agelaki S; Karavassilis V; Kentepozidis N; Samantas E; Peroukidis S; Katsaounis P; Hartabilas E; Varthalitis II; Messaritakis I; Fountzilas G; Georgoulias V; Kotsakis A
    Br J Cancer; 2017 Jun; 117(1):8-14. PubMed ID: 28510571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
    Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
    Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
    Kirschbaum MH; Foon KA; Frankel P; Ruel C; Pulone B; Tuscano JM; Newman EM
    Leuk Lymphoma; 2014 Oct; 55(10):2301-4. PubMed ID: 24369094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
    Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
    Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Angiogenesis in patients with hematologic malignancies].
    Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
    Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
    O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
    Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
    Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
    J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
    Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
    Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
    Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
    Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor.
    Menegaz BA; Cuglievan B; Benson J; Camacho P; Lamhamedi-Cherradi SE; Leung CH; Warneke CL; Huh W; Subbiah V; Benjamin RS; Patel S; Daw N; Hayes-Jordan A; Ludwig JA
    Oncologist; 2018 Mar; 23(3):360-366. PubMed ID: 29212731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.
    Lim WT; Ng QS; Ivy P; Leong SS; Singh O; Chowbay B; Gao F; Thng CH; Goh BC; Tan DS; Koh TS; Toh CK; Tan EH
    Clin Cancer Res; 2011 Aug; 17(16):5481-9. PubMed ID: 21712450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.